Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines. It is given by subcutaneous injection (injection under the skin).
Read the full article on WikipediaTreatment-resistant migraine Clinical criteria: Treatment Phase: Continuing treatment Treatment criteria: Must be treated by a neurologist; OR Must be treated by a general practitioner in consultation with a neurologist, AND Patient must not be undergoing concurrent treatment with the following PBS benefits: (i) botulinum toxin type A listed for this PBS indication, (ii) another drug in the same pharmacological class as this drug listed for this PBS indication. Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must have achieved and maintained at least 50% reduction from baseline in the number of migraine headache days per month, AND Patient must continue to be appropriately managed for medication overuse headache. Patient must have the number of migraine headache days per month documented in their medical records.
“Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta. It potently and selectively binds to CGRPs, which prevents binding to receptors.”
Working under the parallel aged-care framework? Aged-care equivalent →